ライフサイエンスコーパス: transplant recipient

1 ged >=50 years (19 transplant candidates, 20 transplant recipients).

2 t live birth rate (defined as live birth per transplanted recipient).

3 istant Cytomegalovirus retinitis in a kidney transplant recipient.

4 nt, 1 heart transplant recipient, and 1 lung transplant recipient.

5 ded: infant ALL, relapsed ALL, and stem cell transplant recipients.

6 cted DDD was rare, occurring in 0.18% of all transplant recipients.

7 n uncommon opportunistic infection in kidney transplant recipients.

8 ence to immunosuppression in pediatric liver transplant recipients.

9 ression in the growing population of elderly transplant recipients.

10 urologic surgeries, and nonrenal solid-organ transplant recipients.

11 re illness and a high mortality rate in lung transplant recipients.

12 ns to support self-management in solid organ transplant recipients.

13 mmune-mediated kidney diseases and to kidney transplant recipients.

14 ials of eHealth interventions in solid organ transplant recipients.

15 prognosis of female compared with male heart transplant recipients.

16 re collected from the Scientific Registry of Transplant Recipients.

17 h moderate to severe AKI in pediatric kidney transplant recipients.

18 o fatal hyperammonemia syndrome (HS) in lung transplant recipients.

19 tify risk factors for stroke death in kidney transplant recipients.

20 ay 31, 2017 using the Scientific Registry of Transplant Recipients.

21 ders, patients with liver disease, and liver transplant recipients.

22 ics were gleaned from Scientific Registry of Transplant Recipients.

23 pulations, it has not been assessed in heart transplant recipients.

24 tory cells isolated from sex-mismatched lung transplant recipients.

25 edominated (51%) in kidney, liver, and heart transplant recipients.

26 prophylaxis for CMV prevention in D+R- liver transplant recipients.

27 re examined using the Scientific Registry of Transplant Recipients.

28 s with postreperfusion damage in human liver transplant recipients.

29 cells and B cells during ABMR in 105 kidney transplant recipients.

30 the potential to severely impact solid organ transplant recipients.

31 d organ donors, deceased donor families, and transplant recipients.

32 bruary 2017 using the Scientific Registry of Transplant Recipients.

33 vailed as digestive tract pathogens in liver transplant recipients.

34 arable to those previously reported in renal transplant recipients.

35 isk scores on a contemporary cohort of heart transplant recipients.

36 ll as reduction of CNIs for pediatric kidney transplant recipients.

37 es of secondary stroke prevention for kidney transplant recipients.

38 ong heart, lung, liver, pancreas, and kidney transplant recipients.

39 ere identified in the Scientific Registry of Transplant Recipients.

40 ic approach has never been reported in liver transplant recipients.

41 ant outcomes is highly variable among kidney transplant recipients.

42 ultimately improved the outcomes of infected transplant recipients.

43 are limited data describing COVID-19 in lung transplant recipients.

44 ed pathways that overlapped with diabetes in transplant recipients.

45 fever has never previously been reported in transplant recipients.

46 RS-CoV-2 and how it affects organ donors and transplant recipients.

47 ading cause of mortality in kidney and liver transplant recipients.

48 tation, rarely occurs in kidney and pancreas transplant recipients.

49 e involved in regulating lung injury in lung transplant recipients.

50 d outcomes of COVID-19 infection among organ transplant recipients.

51 y in solid organ and hematopoietic stem cell transplant recipients.

52 new opportunities to improve the outcomes of transplant recipients.

53 s retrospective study included 282 HCC liver transplant recipients.

54 unosuppression in a clinical trial of kidney transplant recipients.

55 as evaluated in 2055 biopsies from 775 renal transplant recipients.

56 r prophylaxis for 100 days in 205 D+R- liver transplant recipients.

57 tment of tacrolimus-induced hyperglycemia in transplant recipients.

58 s, and as digestive tract pathogens in liver transplant recipients.

59 costs compared to prophylaxis in D+R- liver transplant recipients.

60 n in immunosuppressed patients, specifically transplant recipients.

61 nts, and Pseudomonas aeruginosa (9%) in lung transplant recipients.

62 nancy that limit the health and longevity of transplant recipients.

63 antly associated with DGF in pediatric renal transplant recipients.

64 factor of urothelial carcinoma (UC) in renal transplant recipients.

65 ith allograft dysfunction in pediatric liver transplant recipients.

66 es of 7 renal transplant recipients, 1 liver transplant recipient, 1 heart transplant recipient, and

67 reatment modalities, and outcomes of 7 renal transplant recipients, 1 liver transplant recipient, 1 h

68 t recipients from the Scientific Registry of Transplant Recipients (2000-2019).

69 Among 251 lung transplant recipients, 50 developed PGD Grade 3.

70 ng clinically and biochemically stable liver transplant recipients, a subset with histological and tr

71 R antibodies in 2 cohorts of pediatric liver transplant recipients: a stable control cohort with norm

72 Among 9845 kidney transplant recipients across centers, 144 were hospitali

73 ndings indicate that immunosuppressed kidney transplant recipients admitted to the hospital with acut

74 Included patients were living-donor kidney transplant recipients aged 18 years and older.

75 Reports of GVHD in kidney and pancreas transplant recipients almost uniformly describe patients

76 : NRP and HOPE in cDCD achieved similar post-transplant recipient and graft survival rates exceeding

77 cember 2018) comprising 4 transgender kidney transplant recipients and 2 transgender living donors wa

78 neumonia has dramatic consequences in kidney transplant recipients and a targeted prophylaxis based o

79 ccurred as urinary tract pathogens in kidney transplant recipients and as digestive tract pathogens i

80 BoV RTI is infrequent in transplant recipients and associated with mild symptoms.

81 of acute and cGVHD in pancreas after kidney transplant recipients and be able to recognize the clini

82 itus (PTDM) affects up to 50% of solid organ transplant recipients and compromises long-term outcomes

83 r retrospective cohort study of primary lung transplant recipients and examined risk factors for DSA

84 olitis [LB]) distribution, is common in lung transplant recipients and increases the risk for chronic

85 Using Scientific Registry of Transplant Recipients and Medicare claims data, we studi

86 or underdeveloped immune systems, including transplant recipients and newborns.

87 pairment in mice with dietary obesity and in transplant recipients and restored immunoquiescence in h

88 e how allergy testing should be performed in transplant recipients and to better understand the impac

89 ients, 1 liver transplant recipient, 1 heart transplant recipient, and 1 lung transplant recipient.

90 urinary pathogens in heart, lung, and kidney transplant recipients, and as digestive tract pathogens

91 s achievable and safe in living-donor kidney transplant recipients, and is associated with fewer infe

92 deficits in long-term potentiation (LTP) in transplant recipients, and LTP impairment in TRANSWT mic

93 ts and as digestive tract pathogens in liver transplant recipients, and Pseudomonas aeruginosa (9%) i

94 tes, experiences with successful aging among transplant recipients, and suggested interventions.

95 been shown to protect seronegative women and transplant recipients, and we should know soon whether t

96 PA(+/0) mice) and of SR-uPA(+/0) bone marrow transplant recipients, and we used bioinformatic tools t

97 Transplant recipients are among the groups for whom the

98 Solid organ transplant recipients are at risk for potentially life-t

99 Whether kidney transplant recipients are capable of mounting an effecti

100 Transplant recipients are frequently exposed to antibiot

101 with expanded T(regs) in T1D and solid-organ transplant recipients are limited by poor T(reg) engraft

102 Surprisingly, despite this risk many transplant recipients are not up-to-date on age appropri

103 Although criteria for kidney transplant recipients are selective, patients with highe

104 Kidney transplant recipients are thought to experience a high r

105 ll summarize the physiology of acute pain in transplant recipients, assess the impact of opioid use o

106 ays during IRI, we treated syngeneic cardiac transplant recipients at 1-hour posttransplant with Anak

107 We identified hospitalized adult kidney transplant recipients at 12 transplant centers in the Un

108 A similar pattern was observed in heart transplant recipients at both elevated and standard risk

109 Kidney transplant recipients at high risk for infections might

110 Lung transplant recipients at our hospital had high rates of

111 ttransplant among 445 consecutive intestinal transplant recipients at our institution since 1994.

112 ent of non-HLA antibodies identifies cardiac transplant recipients at risk of rejection.

113 egistry data from the Scientific Registry of Transplant Recipients between 2006 and 2017, we compared

114 l and histologic phenotyping from 224 kidney transplant recipients between 2011 and 2017.

115 hods: We enrolled 156 of the 209 double lung transplant recipients between December 2017 and March 20

116 Kidney and liver transplant recipients between May 2014 and August 2016 a

117 Renal transplant recipients beyond 1 month posttransplant shou

118 l blood samples obtained from 67 human liver transplant recipients both pre- [portal vein (PV) sample

119 It is widely used in hematopoietic cell transplant recipients but is infrequently utilized after

120 tancy and refusal in the general population, transplant recipients can no longer rely on herd immunit

121 verage of immunosuppressant drugs for kidney transplant recipients ceases 36 months after transplanta

122 Lung transplant recipients commonly develop invasive fungal i

123 spective study that included 255 solid organ transplant recipients confirms that ribavirin is highly

124 Unfortunately, the majority of transplant recipients continue to be underimmunized at t

125 The study included 108 kidney transplant recipients converted from CNI to belatacept b

126 Renal Data System and Scientific Registry of Transplant Recipient data to compare waitlist- and popul

127 Potential transplant recipient data were used to identify the "nex

128 We reviewed the Scientific Registry of Transplant Recipients data from 1987-2017 to identify 96

129 We applied Scientific Registry of Transplant Recipients data from 2011 to 2016 toward the

130 Using Scientific Registry of Transplant Recipients data from 2016-2019, we used an in

131 We studied Scientific Registry of Transplant Recipients data to quantify the association b

132 Using Scientific Registry of Transplant Recipients data, we compared data on observed

133 Using Scientific Registry of Transplant Recipients data, we identified 13 095 SPK tra

134 d mortality using the Scientific Registry of Transplant Recipients database for all kidney transplant

135 The Scientific Registry of Transplant Recipients database was reviewed to identify

136 Pediatric solid organ transplant recipients demonstrate worse overall EF skill

137 ed mean difference in overall EF skills with transplant recipients demonstrating worse EF (g = 0.40;

138 el immunotherapy combinations in solid organ transplant recipients designed to uncouple antitumor and

139 ients to determine how many pediatric kidney transplant recipients developed delayed graft function (

140 In total, 156 of 815 lung transplant recipients developed IFIs (prevalence rate, 1

141 outcomes for simultaneous liver kidney (SLK) transplant recipients developing DGF.

142 ot be used in high-immunological risk kidney transplant recipients due to a perceived increased risk

143 ontroversy about the use of immunotherapy in transplant recipients due to the risk of rejection.

144 for the development of de novo DSA in kidney transplant recipients during the first-year posttranspla

145 Two cohorts of kidney transplant recipients enrolled in the Deterioration of K

146 tudy conducted a serial study of human heart transplant recipients evaluating cardiac effects of diab

147 In the largest national series of EVLP lung transplant recipients, EVLP is associated with early rec

148 We studied kidney transplant recipients experiencing rejection under belat

149 effective in treating CMV-infections in lung transplant recipients failing on currently available ant

150 ere obtained from the Scientific Registry of Transplant Recipients for adults listed and removed from

151 ticenter Deceased Donor Study of 2430 kidney transplant recipients from 1298 donors, we assessed the

152 We included all first kidney-only transplant recipients from 1980 through 2018 from the Au

153 atabase was reviewed to identify adult liver transplant recipients from 2002 through 2016 with MELD s

154 g data, HCV-infected adult first-time kidney transplant recipients from 2014 to 2017 were examined.

155 TR) to study 141 661 Medicare-primary kidney transplant recipients from January 1, 1999 to December 3

156 We report 15 kidney transplant recipients from the Columbia University kidne

157 ted 296 807 adult (age > 17) solitary kidney transplant recipients from the Scientific Registry of Tr

158 Fifty-five transplant recipients (GNB n = 29; SAB n = 26) and 225 n

159 ipient survival (as reported for other organ transplant recipients), graft survival, and uterus trans

160 dosis (group 1) and propensity score-matched transplant recipients (group 2, n = 81) with nonamyloido

161 Kidney transplant recipients had excess stroke deaths, particul

162 d treatment of CMV infections and disease in transplant recipients has been further improved with the

163 f viruses that cause important infections in transplant recipients has been the standard of care for

164 hibitors (CNI) in HLA-sensitized (HS) kidney transplant recipients has not been established.

165 Elderly organ transplant recipients have remained underrepresented in

166 ctors of obesity among pediatric solid-organ transplant recipients (heart, lung, liver, kidney, multi

167 an be safely withdrawn in a subset of kidney transplant recipients, immune mechanisms that underlie s

168 st reported case of yellow fever in a kidney transplant recipient in Brazil and the re-emergence of a

169 al. with unprecedented mortality (18-28%) in transplant recipients in New York City, New York.

170 and recipient CMV-seronegative (D+R-) liver transplant recipients in the current era are incompletel

171 IV-positive to HIV-positive kidney and liver transplant recipients in the USA were examined for evide

172 or allo-sensitization in previously tolerant transplant recipients in whom tolerance maintenance is d

173 report four cases of COVID-19 in solid organ transplant recipients including recipients of kidney, li

174 scRNA-seq of BAL cells from lung transplant recipients indicates that after transplant, t

175 Kidney transplant recipients infected with COVID-19 should be m

176 lmonary disease or interstitial lung disease transplant recipients is associated with alterations in

177 upport the postoperative care of solid organ transplant recipients is evolving.

178 Currently, 1 in 6 pediatric solid organ transplant recipients is hospitalized with a vaccine-pre

179 ving this, we studied Scientific Registry of Transplant Recipients kidney offer data for 3642 pediatr

180 with posttransplantation mortality in kidney transplant recipients (KTR).

181 n therapy is frequently prescribed to kidney transplant recipients (KTRs) for prevention and treatmen

182 class II antibodies and donor HLA in kidney transplant recipients (KTRs) remain unestablished.

183 n D (1,25D) predict renal outcomes in kidney transplant recipients (KTRs), with conflicting results.

184 the MDSC effects on the evolution of kidney transplant recipients (KTRs).

185 a common and burdensome problem among kidney transplant recipients (KTRs).

186 munosuppression Medicare coverage for kidney transplant recipients led to lower costs of -$3077 and 0

187 tory syncytial virus (RSV) infection in lung transplant recipients (LTRs) causes mortality rates of 1

188 In a randomized controlled trial, lung transplant recipients (LTRs) using a mobile health inter

189 ant cause of morbidity and mortality in lung transplant recipients (LTRs).

190 s (HCMV) may cause severe infections in lung transplant recipients (LTRs).

191 rly readmissions and its predictors in liver transplant recipients (LTRs).

192 drug-drug interactions is critical in organ transplant recipient management.

193 Solid organ transplant recipients may be at a high risk for SARS-CoV

194 Kidney transplant recipients may be at a high risk of developin

195 opathy (CAV) is a major contributor of heart transplant recipient mortality.

196 Kidney transplant recipients must take immunosuppressant drugs

197 etween 2006 and 2017, we compared 2048 liver transplant recipients of steatotic livers with 69 394 re

198 We used Scientific Registry of Transplant Recipients offer data from 2009 to 2015 to co

199 disease treatment in hematopoietic stem cell transplant recipients often results in prolonged or inde

200 he clinical course and management of a liver transplant recipient on hemodialysis, who presented with

201 Organ transplant recipients (OTRs) are at increased risk of cu

202 Cs), particularly in immunocompromised organ transplant recipients (OTRs).

203 her these structural features predict kidney transplant recipient outcomes is unclear.

204 rosteatosis grafts in the obese modern liver transplant recipient population.

205 study in pediatric (>=1 to <18 years) kidney transplant recipients randomized at 4 to 6 weeks posttra

206 the randomized SCHEDULE trial, de novo heart transplant recipients received (1) everolimus with reduc

207 ysis suggests that in hypersensitized kidney transplant recipients receiving tacrolimus-based immunos

208 Among D+R- liver transplant recipients receiving valganciclovir as PET, h

209 (+) T cells-in blood samples from 284 kidney transplant recipients recruited 1 year post-transplant a

210 sure immune function in the immunosuppressed transplant recipient relative to infectious risk and all

211 rmovir for the treatment of CMV infection in transplant recipients remain scarce.

212 DWF and DC-GF in kidney transplant recipients represent differing clinical pheno

213 outbreaks occurred, including 13 among renal transplant recipients (RTRs).

214 ommunication shares a protocol for donor and transplant recipient selection during the coronavirus di

215 linical picture is seen, teams managing lung transplant recipients should be aware of this potential

216 Solid organ transplant recipients (SOTr) with coronavirus disease 20

217 The number of solid organ transplant recipients (SOTR), and their life expectancy,

218 s, we used 2010-2018 Scientific Registry for Transplant Recipients (SRTR) data to identify 92 081 adu

219 e actual DDs from the Scientific Registry of Transplant Recipients (SRTR) data, simulations extend ov

220 S) data linked to the Scientific Registry of Transplant Recipients (SRTR) to study 141 661 Medicare-p

221 Utilizing the Scientific Registry of Transplant Recipients (SRTR), we compared outcomes after

222 This pilot study in lung transplant recipients suggests that supplementing postdi

223 yc lymphoma cells, we significantly extended transplant recipient survival.

224 and confidence in managing HCV infection in transplant recipients that in turn has impacted the soli

225 In liver transplant recipients the majority of circulating cells

226 Of the 875 HCV-HCC transplant recipients, the 5-year recurrence-free surviv

227 a regarding the risk of cancer recurrence in transplant recipients, the goal of the AST-sponsored con

228 In simultaneous pancreas-kidney (SPK) transplant recipients, the majority of complications des

229 Among 17 628 kidney transplant recipients, there were 158 stroke deaths and

230 For immunosuppressed transplant recipients, this situation poses great risk.

231 We used the Scientific Registry of Transplant Recipients to determine how many pediatric ki

232 We used the Scientific Registry of Transplant Recipients to identify 149 pediatric en bloc

233 omes, and chemokine and cytokine response in transplant recipients to immunocompetent, nontransplant

234 9 study in which we randomized stable kidney transplant recipients to Tac withdrawal or maintenance o

235 single-center cohort of 64 orthotopic heart transplant recipients transplanted between 1994 and 2014

236 study was conducted across all single kidney transplant recipients, transplanted between 2011 and 201

237 In view of the recent literature, kidney transplant recipients treated by belatacept immunosuppre

238 e compared with a cohort of Medicare-insured transplant recipients, using multivariable survival anal

239 fer of circulating sEVs harvested from human transplant recipients varies depending on the type of tr

240 The impact of these therapies in solid organ transplant recipients was not assessed in clinical trial

241 From 1988 consecutive renal transplant recipients, we analyzed 179 patients undergoi

242 Data System, and the Scientific Registry of Transplant Recipients, we compared population-level char

243 ighly phenotyped prospective cohort of heart transplant recipients, we identified 4 CAV trajectories

244 Using the Scientific Registry of Transplant Recipients, we studied 110,019 adult deceased

245 Only nonimmunized first transplant recipients were eligible.

246 In an observational pilot study, 28 lung transplant recipients were enrolled in a novel postdisch

247 itive to HIV-positive kidney and eight liver transplant recipients were followed from March, 2016, to

248 IV-positive to HIV-positive kidney and liver transplant recipients were followed in three hospitals i

249 Heart transplant recipients were from 4 academic centers (Piti

250 In contrast, transplant recipients were optimistic about their abilit

251 Sixty-nine kidney transplant recipients were randomized from 4 US transpla

252 A total of 2100 adult kidney transplant recipients were recruited from all 23 UK tran

253 hput gene expression datasets of solid organ transplant recipients were retrieved from the Gene Expre

254 iorgan recipients compared with single-organ transplant recipients, which raise ethical questions reg

255 rt, we presented a 63-year-old female kidney transplant recipient who presented with dyspnea and coug

256 port, we present a dual-organ (heart/kidney) transplant recipient who was found to have COVID-19 and,

257 Five-year mortality for kidney transplant recipients who developed an infection was 24.

258 HR: (1.84) 1.91(1.98) , P < .001) for kidney transplant recipients who developed an infection, althou

259 We included consecutive adult liver transplant recipients who had their surgery between July

260 estimated from a cohort of privately insured transplant recipients who receive lifelong immunosuppres

261 r retrospective study of stem cell and organ transplant recipients who received letermovir for the tr

262 proximately 33.6% of nondiabetic solid organ transplant recipients who received tacrolimus developed

263 is retrospective study included 28 pediatric transplant recipients who underwent a total of 32 (18)F-

264 Among 1682 kidney transplant recipients who underwent an allograft biopsy

265 ARS-CoV-2, there is concern that solid organ transplant recipients will be particularly vulnerable to

266 sessed cost-effectiveness between cohorts of transplant recipients willing and unwilling to receive H

267 e reporting the first case of CG in a kidney transplant recipient with kidney disease of unknown caus

268 -PD-1) for ~9 months to a 57-year-old kidney transplant recipient with metastatic cutaneous squamous

269 d ileal tissue from one pediatric intestinal transplant recipient with severe gastroenteritis.

270 present a case report of an upper extremity transplant recipient with trauma-induced rejection.

271 Heart transplant recipients with >=2 known risk factors for re

272 report results on 95 first-time human kidney transplant recipients with 1-year follow-up.

273 ong with serum antibody testing in 18 kidney transplant recipients with active coronavirus disease 20

274 in immunosuppressive therapy for all kidney transplant recipients with active COVID-19 may not be re

275 In contrast, reports of solid organ transplant recipients with clinical features more consis

276 We report a series of 4 lung transplant recipients with CMV-infection and treatment f

277 In this initial cohort, transplant recipients with COVID-19 appear to have more

278 In sum, hospitalized kidney transplant recipients with COVID-19 have higher rates of

279 Kidney transplant recipients with COVID-19 have presentations t

280 ion of the effects of immunomodulators among transplant recipients with COVID-19 infection will be im

281 severity, and disease course in solid organ transplant recipients with COVID-19, including two hospi

282 The trial included 20 kidney transplant recipients with donor-specific, antibody-posi

283 There are limited data on the outcome of transplant recipients with familial Mediterranean fever

284 Retrospective cohort study evaluating renal transplant recipients with first AMR episodes treated wi

285 Eighty-one renal transplant recipients with FMF-associated AA amyloidosis

286 e conducted a retrospective review of kidney transplant recipients with metastatic cancer who receive

287 Six kidney transplant recipients with metastatic cancers that were

288 lantation (CLKT) improves survival for liver transplant recipients with renal dysfunction; however, t

289 port our initial experience with solid organ transplant recipients with SARS-CoV-2 infection at two c

290 ood mononuclear cells were collected from 30 transplant recipients with self-limiting EBV DNAemia (SL

291 al prophylaxis in 205 CMV-seronegative liver transplant recipients with seropositive donors aged olde

292 hylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive donors, high rat

293 Among CMV-seronegative liver transplant recipients with seropositive donors, the use

294 olled trial involving 130 nondiabetic kidney transplant recipients with stable function between 3 and

295 We report that IgG from kidney transplant recipients with TG, but not from those withou

296 aimed to compare the stroke deaths in kidney transplant recipients with the general population and id

297 recommend for or against screening of renal transplant recipients within 1 month, patients with high

298 ces rates of acute rejection in adult kidney transplant recipients, yet little is known about its eff

299 Comorbidity is increasingly common in kidney transplant recipients, yet the implications for transpla

300 ounty-level County Health Ranking data using transplant recipient zip code, and nationwide County Hea